StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Research analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Monday. The brokerage set a “hold” rating on the stock.

A number of other analysts also recently commented on the company. Lake Street Capital decreased their price objective on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. HC Wainwright dropped their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th.

Ekso Bionics Trading Down 0.6 %

Ekso Bionics stock opened at $0.77 on Monday. Ekso Bionics has a 52 week low of $0.76 and a 52 week high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The firm has a market capitalization of $16.92 million, a PE ratio of -1.18 and a beta of 1.47. The business’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.12.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period in the prior year, the firm earned ($0.24) earnings per share. Equities research analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.